histori
matrixassist
laser
desorptionion
maldi
mass
spectrometri
ms
date
back
kara
et
al
first
report
use
organ
molecul
matrix
assist
desorptionion
small
molecul
uv
laser
irradi
koichi
tanaka
colleagu
show
coupl
maldi
timeofflight
tof
mass
analyz
allow
detect
macromolecul
especi
protein
koichi
tanaka
malditof
ms
method
analys
macromolecul
highli
regard
creat
new
opportun
applic
ms
biomed
research
koichi
tanaka
togeth
two
chemist
award
nobel
prize
chemistri
develop
soft
desorpt
ioniz
method
mass
spectrometr
analysi
biolog
macromolecul
past
year
applic
maldi
ms
technolog
qualit
quantit
analys
protein
metabolit
investig
technolog
wide
employ
proteomicmetabolom
research
especi
biomark
discoveri
chapter
aim
updat
reader
advanc
maldi
ms
technolog
clinic
diagnost
applic
go
provid
comprehens
review
maldi
ms
technolog
chapter
cover
malditof
ms
malditoftof
ms
salditof
ms
maldiqqq
ms
selditof
ms
great
potenti
influenc
clinic
diagnost
practic
basic
principl
brief
overview
technolog
provid
extent
allow
reader
understand
potenti
limit
technolog
diagnost
applic
applic
technolog
biomark
discoveri
potenti
use
biomark
quantif
review
practic
concern
possibl
solut
appli
maldibas
ms
technolog
especi
seldi
quantif
discoveri
serumplasma
biomark
also
address
maldi
regard
soft
desorpt
ioniz
method
result
format
ion
without
significantli
break
chemic
bond
use
optim
laser
irradi
particularli
import
obtain
correct
mass
biomolecul
especi
protein
ms
analysi
subsequ
structur
sequenc
inform
obtain
tandem
ms
analysi
indic
name
maldi
matrix
need
assist
desorpt
ioniz
organ
molecul
uv
irradi
desorptionion
effici
differ
type
biomolecul
depend
chemic
use
matrix
exampl
acid
chca
good
matrix
peptid
sinapin
acid
good
intact
protein
superdhb
ie
mixtur
acid
acid
good
glycan
analysi
acid
commonli
use
malditof
ms
analysi
dna
molecul
analyt
mixtur
analyt
need
mix
chemic
matrix
solut
phase
ad
conduct
ms
sampl
plate
dri
analytematrix
cocryst
form
workflow
illustr
fig
subject
maldi
ms
analysi
uv
irradi
analyt
desorb
ioniz
absenc
alkali
metal
ion
andor
halid
ion
cocryst
singli
charg
proton
deproton
molecul
usual
form
mass
molecular
weight
molecul
approxim
equal
mz
valu
mz
valu
respect
presenc
alkali
metal
ion
andor
halid
ion
na
metal
ion
adduct
andor
halid
ion
adduct
may
form
either
posit
neg
charg
molecul
transfer
mass
analyz
separ
accord
masstocharg
mz
ratio
variou
type
mass
analyz
tof
toftof
mass
analyz
commonli
use
coupl
maldi
sourc
kinet
energi
given
group
charg
molecul
direct
proport
charg
state
vacuum
charg
molecul
travel
flight
tube
veloc
invers
proport
squar
root
mz
valu
word
charg
molecul
larger
mz
valu
longer
tof
effici
separ
gener
mass
spectrum
within
resolv
power
tof
mass
analyz
depend
length
flight
path
contrast
commonli
use
mass
analyz
ion
trap
orbitrap
fourier
transform
ion
cyclotron
reson
fticr
mass
analyz
resolv
power
directli
proport
time
charg
molecul
stay
insid
mass
analyz
highthroughput
natur
tof
mass
analyz
make
perfectli
match
maldi
sourc
singl
tof
mass
analyz
allow
effici
structuresequ
elucid
target
analyt
mixtur
analyt
overcom
link
two
tof
mass
analyz
seri
ie
toftof
first
tof
mass
analyz
use
resolv
select
precursor
ion
target
analyt
later
fragment
wherea
second
tof
mass
analyz
use
separ
fragment
ion
gener
tandem
ms
spectrum
discoveri
diseasespecif
biomark
assist
diagnos
still
difficult
import
task
world
one
commonli
use
approach
identif
diseasespecif
biomark
compar
quantit
biomolecul
profil
plasmaserum
specimen
patient
target
diseas
control
subject
without
diseas
high
heterogen
baselin
concentr
variou
circul
biomolecul
among
patient
control
subject
import
obtain
compar
quantit
plasmaserum
biomolecul
profil
patient
control
group
reason
sampl
size
case
highthroughput
technolog
requir
order
complet
analys
specimen
within
accept
period
time
major
advantag
malditof
ms
highthroughput
natur
preprocess
sampl
ms
analys
appli
maldi
sampl
plate
individu
spot
malditof
ms
analysi
sampl
spot
take
less
min
one
hundr
sampl
automat
analyz
within
h
contrast
electrospray
ioniz
esi
anoth
commonli
use
soft
ioniz
technolog
singl
preprocess
sampl
usual
subject
liquid
chromatographi
lc
esi
ms
analysi
result
turnaround
time
min
h
therefor
take
h
analyz
sampl
esi
ms
shotgun
proteom
profil
approach
take
day
obtain
coars
proteom
profil
singl
specimen
least
week
obtain
comprehens
proteom
profil
well
known
malditof
ms
malditoftof
ms
wide
appli
protein
identif
proteom
laboratori
subject
malditof
ms
peptid
protein
predominantli
detect
singli
charg
proton
molecul
high
sensit
one
hand
detect
sensit
malditof
ms
depend
chemic
composit
molecul
hand
gener
detect
sensit
invers
proport
mass
molecul
larg
protein
eg
albumin
usual
least
amount
fmol
pmol
requir
reliabl
ms
signal
clean
prepar
peptid
fmol
readili
detect
malditof
ms
effici
obtain
mass
major
peptid
protein
tryptic
digest
ms
rang
mz
high
accuraci
ppm
extern
mz
calibr
ppm
intern
mz
calibr
result
list
tryptic
peptid
peak
intens
mass
subject
databas
search
obtain
protein
ident
use
tryptic
peptid
mass
fingerprint
algorithm
eg
mascot
individu
tryptic
peptid
subject
tandem
ms
obtain
seri
b
yion
one
malditoftof
ms
instrument
result
list
fragment
ion
peak
intens
mass
subject
databas
search
obtain
protein
ident
use
msm
ion
search
algorithm
describ
previou
section
analyt
embed
analytematrix
cocryst
ms
analysi
major
matric
deriv
benzoic
acid
cinnam
acid
carboxyl
acid
howev
malditof
ms
small
molecul
form
proton
ion
fragment
ion
cluster
ion
caus
intens
chemic
nois
mass
rang
mz
nois
caus
signific
interfer
analys
small
molecul
explain
report
use
malditof
ms
small
molecul
analysi
past
year
although
analys
small
molecul
technic
difficult
report
provid
concret
evid
malditof
ms
feasibl
tool
analysi
small
biomolecul
includ
amino
acid
lipid
olink
glycan
steroid
hormon
etc
addit
matrix
chemic
nois
low
mass
region
prerequisit
format
analytematrix
cocryst
caus
uneven
distribut
analyt
sampl
spot
ms
signal
variou
analyt
vari
significantli
among
cocryst
common
practic
repres
mass
spectrum
singl
sampl
spot
gener
summat
mass
spectra
obtain
differ
posit
within
sampl
spot
result
convent
malditof
ms
method
usual
consid
quantit
semiquantit
howev
reproduc
peak
intens
biomolecul
malditof
ms
spectrum
improv
use
unbias
automat
mass
spectrum
acquisit
protocol
across
sampl
spot
provid
fine
network
eg
nitrocellulos
coat
format
layer
homogen
small
analytematrix
cocryst
unbias
ms
acquisit
protocol
use
nitrocellulos
film
intraassay
interassay
coeffici
variat
cv
normal
peak
intens
peptideprotein
standard
found
suggest
malditof
ms
feasibl
tool
profil
quantifi
peptid
protein
biolog
sampl
plasmaserum
sampl
highli
complex
directli
subject
malditof
ms
analysi
signal
suppress
problem
solv
use
chromatograph
techniqu
enrich
subgroup
protein
match
physicochem
properti
concept
first
introduc
bruker
dalton
inc
bremen
germani
commerci
avail
system
call
clinprot
semiquantit
profil
proteinspeptid
serumplasma
system
variou
type
function
magnet
bead
differ
chromatograph
properti
avail
includ
hydrophob
interact
weak
cation
exchang
weak
anion
exchang
metal
ion
affin
lectin
affin
concanavalin
clinprot
magnet
bead
technolog
licens
perform
malditof
ms
instrument
manufactur
clinprot
system
user
suppli
kit
standard
protocol
togeth
specif
buffer
composit
bind
wash
reagent
disclos
malditof
ms
sensit
technolog
detect
protein
plasmaserum
requir
clinprot
system
accord
supplier
instruct
elut
proteinspeptid
ad
thinlay
chca
subject
malditof
ms
obtain
semiquantit
mass
spectrum
clinprot
technolog
first
report
highli
quantit
cv
normal
proteinpeptid
peak
intens
howev
later
studi
show
cv
manual
robot
assay
report
use
clinprot
system
discoveri
potenti
biomark
human
diseas
oral
cancer
head
neck
cancer
nephrot
syndrom
jimenez
et
al
report
autom
method
compar
clinprot
system
use
hydrophob
magnet
bead
profil
serum
peptid
mass
rang
mz
intraassay
interassay
cv
respect
later
group
develop
strategi
quantit
profil
serum
peptidesprotein
microprepar
purif
correspond
peptidesprotein
parallel
use
hydrophob
strong
anion
exchang
weak
cation
exchang
magnet
bead
method
serum
requir
sinapin
acid
use
chemic
matrix
use
automat
platform
bind
wash
elut
step
use
malditof
ms
instrument
optim
quantit
proteom
profil
intraassay
interassay
cv
found
peptidesprotein
correspond
potenti
diagnost
peak
purifi
parallel
profil
experi
subsequ
work
deciph
protein
ident
potenti
biomark
peak
greatli
simplifi
use
method
recent
identifi
proapolipoprotein
cii
desarginin
variant
serum
amyloid
saa
host
respons
biomark
diagnosi
lateonset
septicemia
necrot
enterocol
preterm
infant
aposaa
score
comput
plasma
saa
concentr
effect
identifi
necrot
enterocolitislateonset
sepsi
case
independ
prospect
cohort
studi
basi
aposaa
score
infant
suspect
diseas
could
stratifi
differ
risk
categori
enabl
neonatologist
withhold
treatment
enact
earli
stoppag
antibiot
nonsepsi
infant
combin
use
hydrophob
magnet
bead
malditoftof
ms
allow
quantit
profil
plasmaserum
peptid
direct
identif
amino
acid
sequenc
peptid
without
need
subsequ
purif
work
villanueva
et
al
attempt
identifi
serum
peptid
pattern
associ
metastat
thyroid
cancer
undertak
approach
found
major
diseaseassoci
peptid
deriv
fibrinopeptid
complement
result
exopeptidas
degrad
specul
proteas
produc
thyroid
cancer
cell
led
format
diseaseassoci
peptid
led
develop
sequencespecif
exopeptidas
activ
test
sseat
test
instead
identif
diseaseassoci
peptid
test
monitor
degrad
artifici
substrat
presenc
individu
patient
sera
malditof
ms
doubl
label
nondegrad
peptid
spike
sampl
intern
standard
time
adjust
adsorpt
processingrel
loss
peak
intens
ratio
degrad
product
correspond
nondegrad
refer
peptid
use
biomark
cv
ratio
report
use
sseat
test
group
could
classifi
metastat
thyroid
cancer
patient
healthi
control
sensit
specif
major
advantag
sseat
test
reproduc
problem
relat
sampl
collect
storag
handl
serum
peptid
profil
analysi
greatli
reduc
furthermor
theoret
use
specif
peptid
sequenc
substrat
differ
diseas
diagnost
sensit
specif
sseat
test
may
improv
immunosorb
assay
immunoturbid
assay
commonli
use
technolog
quantif
specif
protein
biomark
routin
clinic
chemistri
laboratori
technolog
requir
use
specif
antibodi
use
antibodi
allow
sensit
specif
quantif
target
protein
biomark
howev
use
antibodi
caus
uncertainti
measur
affin
specif
antibodi
prepar
specif
antigen
vari
significantli
sourc
sourc
uncommon
immunoassay
kit
differ
manufactur
produc
disconcord
read
furthermor
specif
protein
appear
differ
form
biolog
specimen
includ
glycosyl
variant
free
subunit
metabol
form
typic
exampl
circul
human
chorion
gonadotropin
hcg
use
biomark
diagnosi
pregnanc
hydatidiform
mole
certain
poorli
differenti
cancer
hcg
present
number
form
blood
includ
intact
hcg
nick
hcg
hyper
hypoglycosyl
hcg
hcg
miss
ctermin
extens
free
alphasubunit
larg
free
alphasubunit
free
betasubunit
nick
free
betasubunit
betacor
fragment
blood
sampl
collect
normal
pregnanc
minor
variat
assay
perform
appear
among
commerci
immunoassay
kit
howev
irregular
gestat
immunoassay
result
significantli
differ
among
kit
differ
form
protein
biomark
differ
molecular
weight
readili
differenti
mass
spectrometri
result
reliabl
measur
malditof
ms
use
alon
quantif
protein
biomark
uncomplex
biolog
specimen
urin
exampl
malditof
ms
use
semiquantifi
albumin
urin
diagnosi
albuminuria
approach
requir
pretreat
urin
sampl
result
affect
presenc
interf
substanc
drug
deterg
blood
often
caus
falseposit
falseneg
result
convent
urinari
dipstick
test
glycat
glutathionyl
hemoglobin
measur
direct
malditof
ms
analysi
hemolys
intraassay
interassay
cv
malditof
ms
result
correl
well
result
obtain
use
valid
routin
assay
correl
coeffici
complex
biolog
specimen
like
serum
direct
malditof
ms
analysi
low
abund
protein
possibl
high
medium
abund
protein
serum
mask
signal
target
protein
case
malditof
ms
combin
immunoprecipit
immunocaptur
techniqu
enrich
unmask
signal
protein
biomark
difficult
control
amount
target
protein
recov
antibodi
bead
stableisotop
label
intern
standard
protein
amino
acid
sequenc
must
ad
specimen
normal
variat
exampl
immunoprecipit
amyloidbeta
peptid
cerebr
spinal
fluid
differ
amyloidbeta
isoform
well
correspond
stableisotop
label
intern
standard
appear
individu
peak
expect
mz
valu
malditof
mass
spectrum
quantiti
measur
high
accuraci
intraassay
cv
result
obtain
method
correl
well
result
obtain
elisa
correl
coeffici
use
specif
antibodi
coat
bead
mason
et
al
recent
develop
sensit
method
quantifi
angiotensin
angiotensin
ii
human
plasma
assay
limit
detect
pgml
angiotensin
angiotensin
ii
respect
intraassay
cv
limit
malditof
msbase
quantit
analysi
larg
intact
protein
low
specif
low
sensit
low
resolut
amount
fmol
pmol
requir
gener
reliabl
ms
signal
intact
protein
exampl
concentr
ie
requir
reliabl
measur
intact
bsa
addit
malditof
ms
good
resolut
resolv
larg
intact
protein
accuraci
measur
easili
affect
presenc
protein
contamin
close
molecular
weight
furthermor
widetyp
protein
correspond
mutant
protein
effici
resolv
overcom
limit
one
could
digest
protein
mixtur
first
captur
specif
peptid
commonli
obtain
proteas
digest
ie
proteotyp
peptid
specif
antipeptid
antibodi
coat
bead
final
quantifi
peptid
reflect
protein
concentr
approach
call
imaldi
siscapa
exampl
epiderm
growth
factor
receptor
egfr
molecular
weight
kda
detect
sensit
approach
egfr
shown
fmol
one
malditoftof
ms
instrument
ident
detect
target
peptid
confirm
tandem
ms
could
help
avoid
fals
posit
test
result
use
synthet
proteotyp
peptid
six
protein
correspond
stabl
isotop
peptid
intern
standard
proofofconcept
approach
shown
averag
intraassay
cv
load
amount
fmol
sampl
spot
although
sensit
method
still
magnitud
nanogram
per
millilit
expect
improv
advanc
malditof
ms
near
futur
furthermor
approach
great
potenti
specif
quantif
mutant
protein
result
sens
mutat
gene
sequenc
eg
egfr
mutat
therapi
respons
predictor
nonsmal
cell
lung
cancer
patient
treat
egfr
tyrosin
kinas
inhibitor
major
shortcom
siscapa
imaldi
approach
differenti
differ
form
target
protein
proteotyp
peptid
select
quantif
cover
differ
exampl
proteotyp
peptid
lie
ntermin
region
target
protein
differenti
intact
form
ctermin
truncat
form
detail
imaldi
found
chap
mass
spectrometri
highthroughput
clinic
biomark
assay
multipl
reaction
monitor
written
parker
et
al
long
histori
appli
glycoprotein
biomark
diseas
diagnosi
prognosi
altern
glycosyl
chang
observ
variou
diseas
congenit
disord
glycosyl
syndrom
cdg
liver
diseas
kidney
diseas
cancer
typic
exampl
glycoprotein
biomark
monitor
diseaseassoci
glycosyl
circul
transferrin
still
use
hospit
liver
damag
caus
chronic
alcohol
abus
identif
variou
type
cdg
nowaday
earli
abnorm
microheterogen
serum
transferrin
observ
male
alcohol
alcohol
intox
serum
transferrin
first
use
examin
abnorm
glycosyl
cdg
patient
altern
glycosyl
glycoprotein
glycolipid
common
featur
variou
cancer
involv
numer
way
carcinogenesi
progress
interact
metastasi
tumor
cell
differ
glycosyl
machineri
chang
glycosyl
machineri
cancer
cell
reflect
blood
circul
trace
chang
glycosyl
protein
releas
tumor
poor
specif
tumor
biomark
often
due
fact
also
produc
normal
cell
patholog
condit
howev
problem
reduc
measur
circul
level
variant
carri
cancerassoci
glycosyl
cancer
diagnosi
typic
exampl
alphafetoprotein
afp
compar
total
serum
afp
level
fucosyl
afp
monosialyl
afp
specif
diagnosi
hepatocellular
carcinoma
hcc
elev
mrna
express
fucosyltransferas
human
hcc
tissu
associ
product
tumorspecif
fucosyl
afp
glycoform
serum
level
monosialyl
afp
neg
correl
tissu
level
betagalactosid
malditof
ms
use
identifi
quantifi
diseaseassoci
glycosyl
carri
either
singl
protein
mixtur
protein
case
nlink
glycan
olink
glycan
cleav
protein
prepar
clean
remov
interf
substanc
subsequ
subject
malditof
ms
obtain
mass
spectrum
glycan
fig
normal
peak
intens
individu
glycan
use
estim
rel
level
prepar
intra
interassay
cv
normal
peak
intens
nglycan
report
respect
first
applic
malditofm
analysi
nlink
glycan
transferrin
prepar
fig
affin
isol
serum
sampl
diagnosi
typei
cdg
report
besid
analyz
glycan
cleav
glycoprotein
one
could
use
malditof
ms
examin
diseaseassoci
glycopeptid
obtain
proteolyt
digest
affin
isol
protein
malditof
ms
analysi
glycopeptid
serum
transferrin
appli
cdg
screen
system
diagnosi
typeii
cdg
japan
malditof
sensit
techniqu
serum
requir
screen
typei
typeii
cdg
analyz
glycan
releas
protein
tissu
instead
singl
protein
concept
glycom
appear
maldifticr
ms
first
use
obtain
semiquantit
profil
olink
glycom
serum
identifi
potenti
glycan
biomark
ovarian
cancer
one
year
later
approach
use
discov
potenti
glycan
biomark
breast
cancer
despit
encourag
result
maldifticr
ms
instrument
far
expens
acquir
clinic
laboratori
provid
routin
servic
almost
time
anoth
team
team
report
use
malditof
ms
obtain
semiquantit
profil
serum
nlink
glycom
fig
show
potenti
use
serum
nlink
glycom
fingerprint
diagnos
metastat
prostat
cancer
liver
fibrosi
similar
malditof
ms
approach
use
identifi
serum
nglycan
biomark
diagnos
variou
cancer
includ
hcc
breast
cancer
esophag
adenocarcinoma
ovarian
cancer
case
breast
cancer
serum
nglycan
mz
found
potenti
predictor
patient
respons
trastuzumab
nordhoff
et
al
first
demonstr
use
malditof
ms
detect
measur
mass
nucleic
acid
three
year
later
research
team
led
charl
cantor
show
malditof
ms
use
tool
dna
sequenc
sinc
variou
malditof
msbase
method
develop
applic
molecular
genet
clinic
diagnosi
success
applic
malditof
ms
genotyp
wide
appli
past
year
commonli
use
malditof
ms
method
detect
quantif
singl
base
primer
extens
product
qualit
quantit
analysi
dna
copi
contain
singl
nucleotid
polymorph
snp
malditof
ms
primer
well
design
achiev
good
separ
primer
extens
product
mass
spectrum
genotyp
assay
combin
perform
multiplex
snp
analysi
singl
base
primer
extens
assay
appli
diagnosi
screen
hereditari
diseas
cystic
fibrosi
betathalassemia
fact
diseasespatholog
condit
associ
mutat
specif
gene
specif
set
gene
easili
identifi
quantifi
method
recent
appli
detect
quantif
frequenc
egfr
activ
mutat
nonsmallcel
lung
cancer
tissu
predict
patient
respons
egfr
tyrosin
kinas
inhibitor
method
shown
detect
limit
addit
known
amount
oligonucleotid
welldesign
sequenc
spike
biolog
sampl
competit
primer
extens
reaction
primer
extens
method
use
measur
exact
number
copi
dna
contain
mutat
interest
typic
applic
exampl
detect
hepat
b
viru
variant
four
multiplex
reaction
limit
quantif
hbv
copiesml
besid
dna
primer
extens
method
appli
qualit
quantit
analysi
rna
first
shown
quantif
plasma
placent
rna
allel
ratio
permit
noninvas
detect
prenat
chromosom
aneuploidi
detect
work
open
new
avenu
prenat
diagnosi
matrix
chemic
nois
low
mass
region
mz
make
malditof
ms
inferior
small
molecul
analysi
despit
attempt
made
use
malditof
ms
direct
quantif
biomolecul
amino
acid
lipid
without
need
chemic
derivat
malditof
ms
peak
intens
usual
increas
amount
biomolecul
spike
intern
standard
use
extern
calibr
curv
one
use
malditof
ms
estim
concentr
metabolit
biolog
specimen
calcul
peak
intens
ratio
target
metabolit
intern
standard
gogichaeva
et
al
studi
methyltyrosin
use
univers
intern
standard
quantif
variou
amino
acid
calibr
curv
exhibit
linear
rang
correl
coeffici
betweenday
cv
major
amino
acid
prolin
arginin
except
cv
use
univers
intern
standard
practic
feasibl
use
malditof
ms
identifi
measur
lipid
composit
mz
vldl
ldl
hdl
recent
shown
ms
acquisit
neg
ion
mode
use
instead
typic
chemic
matric
matrix
chemic
nois
greatli
reduc
method
allow
detect
quantif
metabolit
acid
proton
amin
alcohol
carboxyl
acid
phenol
sulfon
high
sensit
high
linear
ms
peak
intens
deproton
metabolit
observ
low
concentr
detect
limit
femtomol
rang
use
matrix
acid
univers
intern
standard
speenrich
variou
bile
acid
speci
plasma
specimen
could
directli
measur
limit
detect
within
rang
anoth
method
reduc
matrix
chemic
nois
replac
chemic
matrix
solid
matrix
approach
call
surfac
assist
laser
desorptionion
saldi
fig
concept
saldi
introduc
sunner
et
al
use
graphit
replac
chemic
matrix
shown
peptid
protein
could
detect
high
sensit
moreov
background
signal
low
mass
region
low
sinc
mani
solid
materi
silicon
carbon
nanotub
graphen
flake
reduc
graphen
oxid
polym
matrix
gold
nanoparticl
shown
use
matric
salditof
ms
analysi
small
biomolecul
includ
carbohydr
amino
acid
lipid
one
hand
use
solidphas
matrix
allevi
matrix
chemic
nois
interfer
problem
low
mass
rang
hand
solv
problem
uneven
distribut
analyt
sampl
spot
use
graphenebas
materi
malditof
mass
spectra
small
molecul
found
highli
reproduc
withinspot
spectrumtospectrum
cv
peak
intens
spermin
graphen
matrix
compar
chca
matrix
recent
lu
et
al
examin
shottoshot
spottospot
reproduc
salditof
mass
spectra
polypropylen
glycol
polym
shottoshot
spottospot
cv
signal
intens
respect
salditof
ms
great
potenti
quantit
profil
small
biomolecul
especi
metabolit
post
genom
era
besid
proteom
metabolom
hot
topic
past
year
mani
research
group
attempt
use
ms
technolog
obtain
quantit
profil
metabolit
patient
specimen
identifi
potenti
metabolit
biomark
compar
profil
subject
without
diseas
lcesi
ms
commonli
use
technolog
research
area
esi
kind
atmospher
pressur
ionizationbas
method
result
occurr
ioniz
suppress
anoth
disadvantag
use
lc
limit
throughput
time
consum
one
want
obtain
comprehens
metabolit
profil
biolog
specimen
biomark
discoveri
studi
highthroughput
natur
malditof
ms
use
malditof
ms
metabolit
profil
attract
altern
shown
use
obtain
quantit
cellular
metabolit
profil
direct
mix
cell
matrix
without
preprocess
exampl
singl
direct
onspot
analysi
human
acut
lymphoblast
leukemia
jurkat
cell
method
detect
metabolit
peak
rang
mz
within
import
note
signal
suppress
metabolit
observ
anoth
metabolit
similar
chemic
structur
present
henc
use
malditof
ms
quantit
analysi
metabolit
data
interpret
care
near
futur
interest
see
whether
metabolit
plasmaserum
directli
profil
use
matrix
nowaday
select
reaction
monitoringmultipl
reaction
monitor
srmmrm
wide
accept
ms
method
reliabl
quantif
small
molecul
typic
implement
esi
tripl
quadrupol
esiqqq
mass
spectromet
see
chap
detail
basic
principl
instrument
qqq
tandem
mass
analyz
use
dedicatedli
srmmrm
method
quadrupol
mass
analyz
use
mass
filter
allow
charg
molecul
specif
mz
valu
pass
mass
analyz
either
subsequ
fragment
detect
undertak
filter
approach
background
nois
greatli
reduc
lead
high
detect
sensit
srm
implement
malditoftof
ms
instrument
report
use
malditoftof
ms
tandem
ms
mode
quantif
avail
gogichaeva
et
al
show
amino
acid
could
fragment
malditoftof
ms
calcul
peak
intens
ratio
indic
fragment
ion
target
amino
acid
indic
fragment
ion
intern
standard
good
correl
mixtur
compon
molar
ratio
indic
fragment
ion
intens
ratio
observ
although
correl
coeffici
coeffici
variat
malditoftof
ms
method
report
studi
highlight
potenti
appli
malditoftof
ms
biomolecul
quantif
recent
use
citrullin
proofofconcept
team
develop
novel
maldtoftof
msbase
quantif
method
call
parallel
fragment
monitor
pfm
method
compar
srm
srm
method
pfm
method
also
requir
least
two
pair
precursor
select
fragment
ion
specif
mz
valu
one
pair
target
molecul
one
pair
intern
standard
stabl
isotop
analog
target
molecul
mass
unit
heavier
use
intern
standard
precursor
ion
target
molecul
intern
standard
specif
isol
first
tof
analyz
time
undergo
fragment
simultan
yield
full
rang
composit
msm
spectrum
srm
pfm
method
peak
area
ratio
select
fragment
target
analyt
intern
standard
use
quantif
use
stabl
isotop
analog
also
abl
minim
error
due
systemat
bia
instrument
normal
recoveri
yield
enrich
analyt
biolog
sampl
quantif
reduc
matrix
nois
low
mass
rang
carbonbas
nanomateri
use
matrix
perform
pfm
method
appear
compar
srmmrm
method
pfm
srmmrm
method
gener
linear
calibr
curv
correl
coeffici
fig
moreov
type
assay
gave
within
betweenday
cv
result
also
show
calibr
curv
highli
reproduc
daili
calibr
use
store
calibr
gener
highli
similar
measur
valu
suggest
pfm
potenti
cost
time
effect
robust
technolog
quantif
biomolecul
routin
clinic
chemistri
laboratori
major
advantag
use
malditoftof
ms
instead
malditof
ms
quantif
malditoftof
ms
higher
detect
specif
sensit
direct
quantif
target
biomolecul
complex
biolog
specimen
partial
enrich
prepar
malditof
ms
enough
resolut
resolv
two
ion
speci
highli
close
molecular
weight
easili
differenti
look
fragment
pattern
even
highli
advanc
malditof
ms
ultrahigh
resolut
maldifticr
ms
abl
differenti
natur
occur
isom
leucin
isoleucin
focus
intact
ion
exactli
similar
molecular
weight
isom
differenti
basi
fragment
ion
furthermor
background
nois
interfer
biomolecul
prepar
like
signal
suppress
biomolecul
share
similar
chemic
structur
minim
measur
ratio
indic
fragment
ion
result
higher
detect
sensit
measur
accuraci
although
qqq
tandem
mass
analyz
usual
coupl
esi
sourc
also
coupl
maldi
sourc
maldiqqq
ms
ident
biomolecul
defin
mass
transit
ion
pair
case
srm
oper
qqq
analyz
mass
filter
target
precursor
ion
fragment
ion
matrix
chemic
nois
low
mass
region
greatli
reduc
compar
quantit
result
obtain
maldiqqq
ms
esiqqq
ms
smallmolecul
pharmaceut
compound
gobey
et
al
demonstr
potenti
maldiqqq
ms
highthroughput
quantif
small
biomolecul
oper
maldiqqq
ms
srmmrm
mode
cv
quantif
small
biomolecul
drug
typic
around
recent
shown
maldiqqq
ms
also
use
measur
protein
biomark
plasma
quantifi
proteotyp
peptid
presenc
correspond
isotop
label
peptid
standard
case
typic
mrm
method
measur
result
highli
compar
obtain
use
esiqqq
ms
technolog
accur
withinday
cv
precis
rel
error
protein
quantif
maldqqq
ms
rel
new
technolog
current
avail
data
limit
howev
recent
report
demonstr
maldiqqq
ms
srmmrm
mode
combin
merit
maldi
ioniz
technolog
convent
srmmrm
approach
reliabl
highthroughput
technolog
biomolecul
quantif
success
applic
maldiqqq
ms
quantif
biomark
human
specimen
forthcom
surfaceenhanc
laser
desorptionion
tof
mass
spectrometri
selditof
ms
variant
malditof
ms
mainli
design
quantit
analysi
protein
biolog
sampl
concept
first
introduc
hutchen
yip
instead
spot
mixtur
protein
maldi
sampl
plate
mixtur
protein
subject
proteinchip
arraybas
retent
chromatographi
malditof
analysi
proteinchip
array
coat
differ
type
chromatograph
materi
hydrophil
hydrophob
cation
exchang
anion
exchang
immobil
metal
affin
antibodi
affin
ligand
affin
etc
select
bind
concentr
protein
match
physicochem
biochem
properti
fig
b
nonspecif
bound
protein
impur
wash
away
suitabl
wash
buffer
retain
protein
final
cocrystal
chemic
matrix
fig
subject
malditof
ms
unbias
detect
proton
protein
fig
e
case
selditof
ms
sinapin
acid
commonli
use
matrix
assist
desorptionion
protein
protein
detect
singli
charg
proton
molecul
present
individu
peak
mass
spectrum
result
proteom
profil
fig
combin
specif
mz
valu
physicochem
properti
reflect
type
proteinchip
array
use
provid
uniqu
ident
individu
protein
selditof
ms
commonli
regard
proteom
fingerprint
technolog
seri
followup
experiment
work
need
purifi
correspond
protein
deciph
true
ident
worth
note
concept
saldi
seldi
combin
solidphas
matrix
captur
biomolecul
particular
physicochem
properti
assist
desorptionion
captur
biomolecul
malditof
ms
analysi
immobil
chca
onto
hydrophob
proteinchip
array
allow
direct
quantit
profil
urin
protein
selditof
ms
without
need
ad
chemic
matrix
sampl
bind
wash
recent
graphenebas
seldi
probe
develop
captur
direct
detect
dna
oligom
without
addit
chemic
matrix
case
malditof
ms
appropri
ms
analysi
condit
selditof
ms
quantit
proteinchip
array
chromatograph
resin
coat
film
hydrogel
provid
network
format
fine
analytematrix
cocryst
furthermor
typic
selditof
ms
experi
unbias
autom
ms
acquisit
strategi
use
ms
signal
laser
shot
obtain
sampl
spot
linear
sweep
variou
posit
regular
space
entir
sampl
spot
sum
form
repres
mass
spectrum
normal
ms
signal
either
total
ion
current
andor
total
peak
intens
intens
valu
proteinpeptid
peak
highli
reproduc
intraassay
interassay
cv
normal
intens
major
seldi
peak
use
standard
experiment
protocol
qualiti
control
strategi
interlaboratori
cv
normal
peak
intens
use
combin
proteinchip
array
differ
chromatograph
coat
selditof
ms
use
obtain
comprehens
semiquantit
profil
protein
molecular
weight
kda
similar
affin
technolog
selditof
ms
appli
variou
type
research
project
appropri
depend
chromatograph
function
group
affin
materi
protein
conjug
coval
proteinchip
array
surfac
use
captur
profil
transcript
factor
coat
dna
materi
specif
sequenc
also
use
studi
effect
dna
methyl
bind
transcript
factor
dna
sequenc
approach
could
help
character
transcript
factor
screen
differ
cellular
regulatori
network
specif
protein
coat
could
use
studi
interact
exampl
use
search
interact
partner
glialcam
proteinchip
array
coat
specif
antibodi
specif
protein
protein
complex
purifi
subsequ
analysi
specif
protein
captur
selditof
ms
identifi
provid
quantit
inform
individu
variant
could
structur
variant
differ
amino
acid
composit
eg
amyloid
beta
peptid
variant
saa
variant
well
variant
differ
posttransl
modif
eg
sglutathionyl
scysteinyl
variant
transthyretin
glycosyl
variant
eosinophil
cation
protein
selditof
ms
commonli
use
quantit
profil
biolog
sampl
search
protein
biomark
theoret
selditof
ms
also
applic
highthroughput
quantif
type
biomolecul
like
metabolit
glycan
follow
section
applic
selditof
ms
protein
biomark
discoveri
review
detail
typic
selditof
ms
experi
biolog
specimen
directli
ad
proteinchip
array
without
preprocess
sever
simpl
step
denatur
dilut
proteinchip
array
assembl
plate
format
bind
wash
procedur
perform
carri
enzymelink
immunosorb
assay
use
proteinchip
array
greatli
simplifi
protein
profil
assay
workflow
anoth
advantag
selditof
ms
capac
high
throughput
mass
spectrum
acquisit
case
malditof
ms
addit
combin
specif
mz
valu
type
proteinchip
array
use
provid
uniqu
ident
individu
protein
major
reason
selditof
ms
wide
use
analysi
biolog
specimen
especi
biomark
discoveri
sinc
first
appear
commerci
avail
platform
today
least
public
applic
selditof
ms
protein
biomark
discoveri
use
analyz
wide
rang
biolog
sampl
exampl
serum
plasma
urin
tear
cerebrospin
fluid
amniot
fluid
tissuecel
lysat
etc
appli
discoveri
potenti
biomark
variou
type
diseas
exampl
cancer
infecti
diseas
autoimmun
diseas
eye
diseas
neurolog
diseas
perinat
neonat
diseas
etc
typic
proteom
profil
experi
individu
biolog
sampl
first
denatur
urea
nonion
solvent
denatur
destroy
noncoval
interact
dilut
appropri
bind
buffer
subsequ
selditof
ms
analysi
approach
small
amount
biolog
sampl
need
serumplasma
specimen
littl
serum
sampl
would
enough
one
reason
popular
selditof
ms
biomark
discoveri
complementari
twodimension
polyacrylamid
gel
electrophoresi
quantit
analysi
intact
protein
fragment
form
vivo
import
point
best
resolv
protein
molecular
weight
rang
kda
selditof
ms
best
resolv
rang
kda
furthermor
highli
hydrophob
protein
membran
protein
protein
isoelectr
point
pi
less
higher
usual
poorli
resolv
satisfactorili
analyz
selditof
ms
anoth
reason
popular
selditof
ms
biomark
discoveri
selditof
ms
great
potenti
use
clinic
diagnost
tool
simplic
assay
procedur
short
turnaround
time
allow
implement
routin
clinic
chemistri
laboratori
could
easili
translat
laboratori
research
find
clinic
use
diagnosisprognosi
could
base
intens
seldi
peak
specif
mz
valu
usag
specif
type
proteinchip
array
base
combin
specif
protein
peak
identifi
use
sever
specif
type
proteinchip
array
protein
correspond
diagnosticprognost
peak
could
purifi
microscal
chromatographi
bind
condit
separ
gel
electrophoresi
final
identifi
use
typic
approach
eg
peptid
mass
fingerprint
tandem
ms
etc
clear
protein
ident
specif
immunoassay
could
develop
clear
major
diseaseassoci
proteom
fingerprint
compos
intact
form
fragment
andor
posttransl
modifi
form
host
respons
protein
apolipoprotein
apolipoprotein
apolipoprotein
apolipoprotein
apolipoprotein
antichymotrypsin
complement
compon
complement
compon
fibrinogen
immunoglobulin
kappa
light
chain
interalpha
trypsin
inhibitor
heavi
chain
haptoglobin
microglobulin
platelet
factor
saa
transthyretin
betathromboglobulin
etc
fact
host
respons
protein
also
identifi
potenti
biomark
serumplasma
proteom
profil
compar
use
techniqu
magnet
beadsbas
malditof
ms
even
shotgun
proteom
profil
lcesim
use
signatur
hostrespons
protein
diseas
biomark
pro
con
major
advantag
host
respons
patient
help
amplifi
signal
presenc
particular
diseas
may
help
identifi
diseas
earli
stage
major
disadvantag
specif
hostrespons
signatur
care
valid
claim
diseasespecif
biomark
similar
symptom
gener
specif
hostrespons
protein
signatur
easili
found
diseas
although
selditof
ms
popular
technolog
biomark
discoveri
doubt
reliabl
technolog
discuss
issu
would
like
emphas
problem
restrict
seldi
proteom
profil
studi
problem
observ
mani
selditof
ms
studi
may
selditof
ms
first
highthroughput
technolog
allow
quantit
profil
comparison
serumplasma
protein
larg
number
patient
sampl
within
short
period
time
much
serum
proteomicmetabolom
profil
data
obtain
use
technolog
avail
believ
similar
problem
observ
section
select
biomark
discoveri
studi
employ
selditof
ms
technolog
use
exampl
review
issu
typic
exampl
applic
selditof
ms
diagnosi
ovarian
cancer
petricoin
et
al
identifi
pattern
seldi
peak
could
complet
differenti
ovarian
cancer
case
noncanc
case
train
set
mask
set
diagnost
pattern
achiev
sensit
specif
unfortun
data
set
reanalyz
team
found
signific
nonbiolog
experiment
bia
cancer
control
subject
featur
nois
region
seldi
mass
spectra
allow
discrimin
control
subject
cancer
patient
analysi
result
suggest
cancer
control
sampl
analyz
separ
chang
experiment
protocol
middl
studi
anoth
import
exampl
identif
seldi
peak
diagnosi
prostat
cancer
use
copper
ii
ion
load
metal
affin
proteinchip
array
pilot
singlecent
studi
show
serum
protein
fingerprint
use
diagnosi
prostat
cancer
classifi
blind
test
sampl
sensit
specif
found
respect
subsequ
seri
followup
studi
perform
valid
valu
serum
proteom
profil
proteinchip
array
diagnosi
prostat
cancer
allow
valid
carri
six
research
center
standard
protocol
qualiti
control
system
develop
serum
sampl
prostat
cancer
patient
benign
prostat
hyperplasia
case
normal
control
age
racematch
eastern
virginia
medic
school
evm
use
construct
decis
algorithm
classifi
prostat
cancer
patient
normal
control
provid
four
institut
test
sampl
distribut
six
laboratori
analysi
final
conclus
decis
algorithm
unsuccess
separ
cancer
control
analysi
experiment
data
biomark
discoveri
indic
sampl
sourc
major
factor
affect
result
inappropri
select
control
subject
ie
select
bia
one
major
caus
system
bia
select
bia
inform
bia
appear
diseas
control
subject
recruit
two
differ
popul
two
differ
clinic
exampl
three
laboratori
attempt
use
selditof
ms
identifi
biomark
detect
sever
acut
respiratori
syndrom
sar
adult
two
three
studi
control
case
recruit
clinic
patient
type
respiratori
infect
includ
control
saa
concentr
found
significantli
higher
sar
patient
control
one
studi
includ
saa
diagnost
model
detect
sar
third
studi
perform
team
sar
patient
control
subject
recruit
clinic
control
subject
suspect
sar
case
later
proven
neg
sar
studi
selditof
ms
assay
immunoassay
show
saa
elev
sar
patient
howev
saa
level
found
much
higher
control
group
indic
saa
use
biomark
diagnosi
sar
three
studi
clearli
illustr
import
recruit
diseas
control
case
clinic
biomark
studi
confound
bia
also
control
control
biomark
found
could
relat
characterist
diseas
group
relat
diseas
patient
gastroenterolog
cancer
may
lose
appetit
lead
nutrit
malnutrit
becom
one
confound
factor
differenti
seldi
peak
could
relat
nutrit
statu
hepat
virusrel
liver
cancer
well
known
gender
one
confound
factor
smoke
wellknown
confound
factor
lung
cancer
level
consider
amount
blood
protein
chang
respons
smoke
biomark
discoveri
even
though
diseas
control
case
recruit
clinic
unknown
confound
factor
still
exist
recent
gastric
cancer
studi
attempt
use
postop
serum
sampl
verifi
valid
potenti
proteom
marker
found
compar
diseas
control
case
clinic
surprisingli
potenti
biomark
could
show
revers
serum
level
remov
tumor
patient
strongli
suggest
differenti
seldi
peak
gastric
cancer
control
group
specif
associ
gastric
cancer
associ
certain
characterist
gastric
cancer
patient
sar
studi
identifi
clinic
biochem
variabl
significantli
alter
sar
patient
attempt
verifi
potenti
diagnost
seldi
peak
consid
significantli
correl
least
two
diseaseassoci
biochemicalclin
paramet
sarsspecif
fig
similar
gastric
cancer
studi
differenti
seldi
peak
reject
sar
studi
gastric
cancer
studi
sar
studi
highlight
high
risk
fals
discoveri
simpli
consid
differenti
seldi
peak
potenti
biomark
presenc
differenti
seldi
peak
like
caus
confound
bia
restrict
studi
employ
selditof
ms
group
recent
attempt
identifi
circul
host
respons
biomark
diagnosi
lateonset
sepsi
necrot
enterocol
preterm
infant
suspect
diseas
use
hydrophob
magnet
bead
malditof
ms
use
longitudin
sampl
verifi
clinic
relev
differenti
proteom
featur
reject
fig
encouragingli
diagnost
valu
verifi
proteom
featur
subsequ
confirm
prospect
studi
one
reduc
system
bia
singl
center
studi
verif
longitudin
sampl
correl
known
diseaseassoci
chang
one
also
reduc
system
bia
use
sampl
multipl
center
multicent
design
provid
unbias
clinic
valid
proteom
diagnost
model
zhang
chan
propos
multicent
design
help
elimin
system
bias
sampl
siteassoci
confound
variabl
biomark
discoveri
biomark
discoveri
phase
case
independ
site
use
separ
independ
identifi
potenti
biomark
potenti
biomark
differ
site
crosscompar
produc
common
set
valid
phase
clinic
valu
common
set
valid
use
independ
sampl
addit
site
use
multicent
design
panel
ovarian
cancerassoci
protein
biomark
identifi
blood
sampl
selditof
ms
final
becam
first
vitro
diagnost
multivari
index
assay
ivdmia
proteom
biomark
recent
clear
us
fda
food
drug
administr
global
research
effort
develop
biomed
applic
maldibas
technolog
past
year
shown
great
promis
facilit
biomark
discoveri
clinic
diagnost
applic
concept
maldi
saldi
seldi
pfm
complementari
theoret
technolog
combin
lead
next
gener
maldi
ms
technolog
although
selditof
ms
commonli
regard
proteom
fingerprint
technolog
selditof
ms
also
applic
quantit
profil
type
biomolecul
glycan
metabolit
biomark
discoveri
identif
diagnost
fingerprint
furthermor
seldi
coupl
toftof
ms
target
quantif
specif
metabolit
small
protein
proteotyp
peptid
larg
protein
achiev
undertak
pfm
approach
enrichmentpurif
procedur
much
simplifi
bind
surfac
seldi
chip
made
materi
also
assist
laser
desorpt
ioniz
process
ie
combin
seldi
saldi
selditoftof
ms
setup
becom
instrument
costeffect
measur
biomark
ultrahigh
throughput
high
detect
sensit
specif
ultim
tof
toftof
analyz
miniatur
portabl
size
without
sacrif
resolut
medic
diagnost
applic
maldibas
technolog
bedsid
even
home
becom
possibl
